Popular Weight-Loss Injections Now Require FDA Warning for Sudden Blindness

2026-11-10 companies

Washington, Monday, 9 November 2026.
US regulators mandated warning labels on popular weight-loss drugs after clinical data linked them to an untreatable optic nerve condition that can cause permanent, sudden vision loss.

FDA Mandates Warning Labels for GLP-1 Drugs

The U.S. Food and Drug Administration (FDA) has ordered pharmaceutical manufacturers to update warning labels for widely prescribed GLP-1 receptor agonists, including Ozempic (Novo Nordisk, NYSE: NVO) and Zepbound (Eli Lilly, NYSE: LLY), to include risks of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden, permanent vision loss [1][2][3][4][5]. The decision, announced on Monday, November 9, 2026, requires all GLP-1 drugs—such as Novo Nordisk’s Wegovy, Ozempic, and Rybelsus, as well as Eli Lilly’s Mounjaro and Zepbound—to add warnings about the potential increased risk of NAION in the ‘Warnings and Precautions’ section of their labels [3][4].

NAION: A Rare but Serious Condition

NAION is a condition characterized by reduced blood flow to the optic nerve, leading to sudden, painless vision loss that may be permanent in some cases [2][3][4]. While the underlying cause remains incompletely understood, the FDA’s decision follows growing concerns over a potential link between GLP-1 therapies and the condition. The agency cited data from clinical trials, post-marketing surveillance, and observational studies, including a meta-analysis of 126 trials involving 134,253 patients [3]. This analysis found a NAION incidence rate of 6.4 events per 100,000 patient-years (PY) in GLP-1 users compared to 3.8 events per 100,000 PY in comparator groups [3][5]. However, the FDA noted that animal data did not identify a clear mechanism for how GLP-1 drugs might increase NAION risk [3].

Regulatory Action and Industry Response

The FDA’s mandate introduces regulatory and liability risks for pharmaceutical giants Novo Nordisk and Eli Lilly, whose GLP-1 drugs have seen surging adoption for diabetes management and weight loss [1][2][4][5]. Both companies acknowledged the FDA’s decision, with Novo Nordisk stating that patient safety is a ‘top priority’ and reaffirming confidence in the benefits of its drugs outweighing the risks [2][4]. Eli Lilly did not immediately respond to requests for comment [2]. The FDA’s action follows a 2024 study published in JAMA Ophthalmology, which found that diabetes patients prescribed semaglutide—a key ingredient in Ozempic, Wegovy, and Rybelsus—were four times as likely to develop NAION as those not prescribed the drug [4][5].

Broader Implications for Patients and Markets

The FDA’s warning underscores the need for patients and healthcare providers to weigh the risks of GLP-1 therapies against their benefits, particularly for those with pre-existing conditions like Type 2 diabetes, sleep apnea, or hypertension, which share risk factors with NAION [2][3][4]. NAION is the second most common optic nerve disease in the U.S., with an estimated incidence of 10 cases per 100,000 people over age 50 [4]. The FDA’s decision may also spark broader economic discussions, including the potential impact of side effects on user activity and spending [3]. For now, regulators and manufacturers emphasize the importance of ongoing monitoring and patient education as the new warnings take effect.

Sources

GLP-1 FDA warning